NCT02654158 - Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection | Biotech Hunter

Enrollment

2,400

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

Acute Upper Respiratory Infection

Interventions

DRUG

Low-dose of Fuganlin Oral Liquid

"less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day"

DRUG

High-dose of Fuganlin Oral Liquid

"less than 1 years old: 10mL each time and three times a day~1\~3 years old: 20mL each time and three times a day~4\~6 years old: 20mL each time and four times a day~7\~12 years old: 20mL each time and five times a day"

Trial Locations (1)

440100

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou